Monte Rosa Therapeutics (NASDAQ:GLUE) COO Jennifer Champoux Sells 2,176 Shares of Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) COO Jennifer Champoux sold 2,176 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $19.00, for a total value of $41,344.00. Following the transaction, the chief operating officer owned 62,371 shares of the company’s stock, valued at approximately $1,185,049. This represents a 3.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jennifer Champoux also recently made the following trade(s):

• On Wednesday, May 27th, Jennifer Champoux sold 2,175 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $43,500.00.

Monte Rosa Therapeutics Stock Down 0.5%

NASDAQ:GLUE opened at $18.31 on Friday. The firm’s fifty day simple moving average is $18.63 and its 200 day simple moving average is $18.48. The stock has a market cap of $1.55 billion, a P/E ratio of -12.37 and a beta of 1.60. Monte Rosa Therapeutics, Inc. has a twelve month low of $4.12 and a twelve month high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). The company had revenue of $4.21 million during the quarter, compared to analysts’ expectations of $10.95 million. Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%. On average, analysts expect that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Institutional Trading of Monte Rosa Therapeutics

Hedge funds have recently made changes to their positions in the stock. Seven Fleet Capital Management LP grew its stake in shares of Monte Rosa Therapeutics by 463.3% in the 1st quarter. Seven Fleet Capital Management LP now owns 22,530 shares of the company’s stock worth $371,000 after buying an additional 18,530 shares during the last quarter. Bank of America Corp DE raised its stake in Monte Rosa Therapeutics by 73.3% during the first quarter. Bank of America Corp DE now owns 387,542 shares of the company’s stock valued at $6,375,000 after buying an additional 163,971 shares during the last quarter. Janus Henderson Group PLC purchased a new position in Monte Rosa Therapeutics during the first quarter valued at $11,294,000. Empowered Funds LLC boosted its holdings in Monte Rosa Therapeutics by 9.8% in the first quarter. Empowered Funds LLC now owns 305,398 shares of the company’s stock worth $5,024,000 after acquiring an additional 27,321 shares in the last quarter. Finally, Exome Asset Management LLC bought a new stake in Monte Rosa Therapeutics in the first quarter worth $2,953,000. 79.96% of the stock is owned by institutional investors.

Analysts Set New Price Targets

GLUE has been the topic of several research reports. Guggenheim cut their price objective on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research report on Wednesday, March 18th. JPMorgan Chase & Co. raised their target price on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Wells Fargo & Company dropped their price target on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Weiss Ratings raised Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Finally, Wall Street Zen lowered Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.50.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.